Citations

Clear

396 citation(s) found for "Spinner, M".

Perineural spread of colorectal carcinoma into the sciatic nerve with positive circulating tumor DNA test: illustrative case
Texakalidis, Pavlos , Prideaux, Cara C. , Dyck, P. James B., Spinner, Robert J. , Spinner, Robert J , Xie, Hao

Mayo Clinic

Journal of Neurosurgery: Case Lessons | April 8, 2026 | Volume: 11 | Issue: 12 | Pages: No page available

10.3171/case25997 | PMID 41871390 Get It

BACKGROUND Perineural spread (PNS) of colorectal carcinoma (CRC) is a rare and challenging diagnosis. Its clinical and radiological presentation is often subtle and can overlap with radiation-induced neuropathy and malignant nerve tumors, complicating timely diagnosis. The role of circulating tumor DNA (ctDNA) in the detection of PNS has not been previously described. OBSERVATIONS A 48-year-old man with a history of rectal cancer and perineural invasion presented with progressive, refractory sciatic neuropathic pain. Conventional surveillance imaging was initially negative despite subtle rising of carcinoembryonic antigen and ctDNA levels. Subsequent MRI revealed abnormalities of the lumbosacral plexus and sciatic nerve, and fascicular biopsy confirmed metastatic CRC involving the sciatic nerve, establishing the diagnosis of PNS. LESSONS This case highlights PNS as a rare but important consideration in patients with focal neuropathic symptoms and prior CRC. Circulating tumor DNA positivity may serve as an early indicator of occult tumor activity even within the nerves when imaging is equivocal. However, currently histopathological confirmation remains the only definitive method to distinguish PNS from alternative diagnoses and is essential to guide appropriate management. https://thejns.org/doi/10.3171/CASE25997
Bertolotti joint–related cyst: illustrative case
Chow, W , Spinner, Robert J., Amrami, Kimberly K., Elder, Benjamin D. , Steinmetz, Michael P., Chow, William D, Spinner, Robert J , Chow, William D., Spinner, Robert J. , Amrami, Kimberly K. , Steinmetz, Michael P.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | March 19, 2026 | Volume: 11 | Issue: 11 | Pages: No page available

10.3171/case25948 | PMID 41871426 Get It

BACKGROUND Bertolotti syndrome is an underrecognized cause of chronic low back pain. Back pain generated from Bertolotti syndrome is believed to result from altered weight dissipation mechanics and/or instability of the pseudoarticulation, while local nerve root compression may result in radiculopathy. Here, the authors describe the findings of a patient with treatment-refractory low back pain found to have a cystic lesion arising from a Bertolotti joint causing L5 nerve root compression. To their knowledge, this has not been previously described in the literature. OBSERVATIONS Despite early recognition of Bertolotti syndrome, the patient’s back pain remained resistant to many years of both conservative and surgical management. The novel finding of a cyst arising from the pseudoarticulation complicated the management. The patient is scheduled to undergo further surgery this year. LESSONS This case highlights a pseudocyst associated with a Bertolotti joint. The cyst introduced additional clinical uncertainty to what is already an uncommon and difficult to treat condition. Resection of the Bertolotti joint failed to improve the patient’s symptoms. Postoperatively, a complex hemorrhagic pseudocyst was seen on imaging, possibly due to the pseudoarticulation with persistent motion. Ongoing efforts to characterize Bertolotti syndrome and its associated imaging findings are necessary to better optimize management strategies in these patients. https://thejns.org/doi/10.3171/CASE25948
Preoperative intra-articular fluorescein injection to detect the articular branch at surgery on a sural intraneural ganglion cyst at the ankle: illustrative case
Gogoi, Rahul , Spinner, Robert J, Amrami, Kimberly K, Ruiter, Godard C W de, Spinner, Robert J , Spinner, Robert J. , Amrami, Kimberly K. , Coerkamp, Emile G. , Ruiter, Godard C. W. de

Mayo Clinic

Journal of Neurosurgery: Case Lessons | March 19, 2026 | Volume: 11 | Issue: 10 | Pages: No page available

10.3171/case251018 | PMID 41802287 Get It

BACKGROUND Intraneural ganglion cysts (IGCs) are mucinous lesions that originate from adjacent synovial joints. According to the articular theory, synovial fluid tracks from a joint into the parent nerve through an articular branch. In uncommon sites such as the sural nerve, this connection can be difficult to identify. This report illustrates the use of a preoperative intra-articular fluorescein injection as a tool to identify the articular branch during surgery. OBSERVATIONS A 60-year-old woman presented with lateral foot pain, numbness, and a palpable mass along the left sural distribution. MRI showed a large cyst extending along the course of the sural nerve with connection to the subtalar joint. Fluorescein was injected preoperatively into this joint to detect the articular branch intraoperatively with ultraviolet illumination. The connection was transected at the joint origin, and the cyst was decompressed, preserving the parent nerve. Postoperatively, the patient had complete pain relief and sensory recovery, and MRI at 3 and 8 months confirmed resolution of the cyst. LESSONS Sural IGCs conform to the articular theory and can be managed effectively by transection of the articular branch. Preoperative intra-articular fluorescein injection is a useful tool to detect the articular branch that can be difficult to find in sural IGCs. https://thejns.org/doi/10.3171/CASE251018
Bicentric Study of AI-Based Differentiation of Malignancy in Skull Base Schwannomas and Prognostic Prediction
Šťastná, Daniela , Dang, Danielle , Macfarlane, Robert, Mannion, Richard, Giannini, Carolina, Spinner, Robert, Gompel, Jamie J. Van, Link, Michael J., Axon, Patrick , Tysome, James Russell , Donnelly, Neil P. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 27, 2026 | Volume: 87 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1819412 Get It

Identification of the Paraneurium With 7 T MRI in Normal Nerve Anatomy and Various Nerve Pathologies
Piyawattanametha, Nontaphon , Ruiter, Godard C. W. de, Reina, Miguel A., Amrami, Kimberly K., Spinner, Robert J., Spinner, Robert J , Marek, Tomáš , Ruiter, Godard C W de, Reina, Miguel Ángel , Amrami, Kimberly K. , Spinner, Robert J.

Mayo Clinic

Clinical Anatomy | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ca.70095 | PMID 41708582 Get It

ABSTRACT The paraneurium is a distinct connective tissue sheath that loosely envelopes the epineurium. The space between the para‐ and epineurium (the subparaneurial compartment) holds significant clinical relevance, serving as a target for deposition of regional anesthesia and a potential pathway for the pathological spread of cysts and tumors. However, visualization of the paraneurial layer, as a separate structure from the epineurium, remains challenging with conventional MRI, especially in the absence of pathology. This study evaluated the visualization of the paraneurium using ultra‐high‐field 7‐Tesla (7 T) MRI compared to conventional field strengths. We assessed normal nerve anatomy and a spectrum of pathological cases, including intraneural ganglion cysts, schwannomas, intraneural perineuriomas, and metastatic melanoma. The results demonstrated that 7 T MRI provides superior resolution and delineation of the paraneurium compared to 1.5 and 3 T systems. In normal anatomy, T1‐weighted and proton density (PD) sequences provided optimal contrast between the paraneurium and surrounding adipose tissue. In contrast, for pathological cases, T2‐weighted sequences with fat suppression were superior for depicting the paraneurium and identifying subparaneurial involvement. In conclusion, 7 T MRI offers a significant advantage in identifying the thin paraneurial layer. This capability provides valuable insights into the pathogenesis of tumor spread and holds promise for improving pre‐operative planning and clinical decision‐making in peripheral nerve pathology.
Abstract PS4-03-10: Assessing the impact of real-time serial circulating tumor cell results on the management of patients with metastatic breast cancer
Giridhar, K. V., Zahrieh, David M. , Hanna, Mina, Singh, A., Al‐Hattab, Eyad, Schumacher, P., Carroll, J., Hoppenworth, Jenna, Haddad, TC, Tevaarwerk, A. J., Rudder, B., Choong, G. M., Basu, S. , Leon-Ferre, R. A., O'Brien, T., Lewis, A., Snoo, F. de, Stork-Sloots, L., Kuhr, F. K., Lazaro, S., Prendergast, R., Spinner, D. S., Goetz, M. P., Carroll, J., Tevaarwerk, Amye J., Basu, S., Leon‐Ferre, Roberto A. , Snoo, Femke De , Stork‐Sloots, Lisette, Goetz, Matthew P.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS4-03-10-PS4-03-10

10.1158/1557-3265.sabcs25-ps4-03-10 Get It

Abstract Introduction Serial assessments of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) provide independent prognostic significance for progression free survival and overall survival. A low CTC burden (<5 CTCs / 7.5mL blood) at baseline is favorable prognostically, and reduction of CTCs during treatment indicates response to treatment (Janni, CCR 2025). Despite increasing evidence supporting its clinical validity, real-time serial CTC enumeration has not been utilized broadly in clinical practice in the U.S. The ACT-MBC study is a prospective observational study to evaluate the impact of serial CTC testing on treatment decisions and response assessment (NCT05662345). Provider (physician or advanced practitioner) perception of CTC testing is measured with questionnaires at baseline (PQ1), and for each pt during the first restaging visit (PQ2), and at the end of the study (PQ3). We previously reported PQ1 results (Giridhar, SABCS 2024). Here, we report on results of PQ2. Methods ACT-MBC prospectively enrolled patients (pts) at Mayo Clinic Rochester and Mayo Clinic Health Systems sites (Mankato, Albert Lea and Eau Claire). Pts with MBC were enrolled at time of progressive disease during any line of therapy (TNBC) or ≥2nd line metastatic therapy for ER+/HER2- disease. Pts were tested for CTCs using the FDA-cleared CellSearch® assay which included enumeration and biomarker testing on CTCs for ER, HER2, and PD-L1. The treating clinician determined the regimen and timing of restaging scans. CTC testing was performed once per cycle (every 3-4 weeks) with results returned to the treating provider within 7 days. We descriptively summarized PQ2 responses from providers who had at least one on-treatment CTC result available by the first restaging visit. We report the proportion (90% CI) of providers who agreed or strongly agreed that assessing CTCs enhanced their ability to determine response to therapy and that the CTC results helped guide their decision to continue or change therapy (co-primary endpoints) while accounting for within provider correlation. Results As of June 25, 2025, 15 providers enrolled a median of 2 pts each (range: 1 to 15 pts) and completed PQ2 surveys on 40 pts. 7 providers (47%) practiced in the community setting and 4 (27%) were nurse practitioners. Most pts were female (98%), White (98%), and had ER+/HER2- MBC (80%). Baseline (C1) CTC results were elevated (≥5 CTCs) in 24 (60%) pts (CTC range 0-609). At C2 (n=39), CTC values remained undetected in 7 pts, decreased in 21 pts, increased in 8 pts, and remained unchanged in 3 pts. At PQ2 (n=40), based on clinician interpretation of radiographic findings, results showed 2.5% of pts with complete response, 20% with partial response, 25% with stable disease, 17.5% with mixed response, and 35% with progressive disease. Clinicians reported that CTC results were concordant with imaging results in 34 (85%) responses, discordant with imaging in 7.5% of responses, and unclear in the remaining 7.5% of responses. Most clinicians (82.5%) agreed or strongly agreed that assessing CTCs enhanced their ability to determine response to therapy (90% CI: 68.3%, 96.7%). Further, 70% of providers agreed or strongly agreed that the CTC results helped guide their decision to continue or change therapy (90% CI: 50.8%, 89.2%). 32.5% of the time, CTCs results influenced the timing of the first restaging scans. In 11/25 pts without progressing disease, CTC results influenced the timing of future scans. In the 7/8 pts with a mixed response at first restaging scans with decreasing CTCs, 4 remained on the same systemic therapy. Conclusions Oncologists in academic and community practice responded that serial CTC assessments enhance ability to determine response of therapy, guide decisions to continue or change treatments, and influence timing of radiographic assessments. Citation Format: K. V. Giridhar, D. Zahrieh, M. Hanna, A. Singh, E. Al-Hattab, P. Schumacher, J. Carroll, J. Hoppenworth, T. Haddad, A. Tevaarwerk, B. Rudder, G. M. Choong, S. Basu, R. A. Leon-Ferre, T. O'Brien, A. Lewis, F. de Snoo, L. Stork-Sloots, F. K. Kuhr, S. Lazaro, R. Prendergast, D. S. Spinner, M. P. Goetz. Assessing the impact of real-time serial circulating tumor cell results on the management of patients with metastatic breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS4-03-10.
Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology
Advani, Ranjana H., Kelsey, C., Armand, Philippe, Bello, Celeste, Benitez, Cecil M. , Chen, Weina , Cherian, Sheen , Czader, Magdalena , Dabaja, Bouthaina, Daly, Megan E., Gordon, L. I., Hansen, Neil, Herrera, Alex F. , Hochberg, Ephraim P. , Hoppe, Richard T., Isufi, Iris, Johnston, Patrick B., Kelly, Kara M, Kenkre, Vaishalee P. , Lynch, R., Morgan, David, Rabinovitch, R., Salavati, Ali, Sano, Dahlia , Svoboda, J., Yahalom, Joachim, Yang, Joanna C. , Stehman, Katie, Advani, Ranjana H. , Hoppe, Richard T. , Advani, Ranjana H , Hoppe, Richard T , Kelsey, Chris R. , Armand, Philippe , Bond, David A. , Dabaja, Bouthaina, Daly, Megan, Frosch, Zachary AK , Hansen, Neil, Johnston, Patrick B, Kelly, Kara M , Kline, Justin Paul , McConathy, Jonathan , Niu, Alex , Paul, Suman , Rabinovitch, Rachel , Salavati, Ali , Shah, Harsh , Spinner, Michael A. , Svoboda, Jakub , Winter, Jane N. , Yahalom, Joachim , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: 41-60

10.6004/jnccn.2026.0006 | PMID 41671432 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hodgkin lymphoma provide expert, multidisciplinary recommendations for the diagnosis and treatment of Hodgkin lymphoma. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Hodgkin Lymphoma focuses on the management of newly diagnosed and relapsed/refractory classic Hodgkin lymphoma in adults aged 18 to 60 years.
Neurapraxia in Time and Space
Davis, Gavin A. , Hanna, Amgad S., Tubbs, R. Shane, Spinner, Robert J., Davis, Gavin A , Klein, Christopher J , Hanna, Amgad S. , Klein, Christopher J. , Spinner, Robert J.

Mayo Clinic

Neurosurgery | February 5, 2026 | Volume: 99 | Issue: 3 | Pages: 530-536

10.1227/neu.0000000000003952 | PMID 41642001 Get It

Since its introduction into medical terminology by Lord Henry Cohen in 1941, the term “neurapraxia” has become established in the neurological and neurosurgical lexicon, although it is often misused or misspelled. It denotes a transient dysfunction of a peripheral nerve, as distinct from axonotmesis and neurotmesis, which describe more significant structural injuries to a peripheral nerve. To expand our understanding of neurapraxia, it is necessary to examine the phenomenon in both temporal and spatial contexts. This study examines neurapraxia in: (A) Time—(1) the origins of the term neurapraxia and (2) the time-course of a neurapraxic injury and its recovery, and (B) Space—(3) the microstructure of a neurapraxic injury and (4) the locations of neurapraxic injuries within the peripheral nervous system. We demonstrate that the term neurapraxia encompasses both a temporal and a spatial definition. In time, it applies to transient peripheral nerve palsy, from which recovery occurs before there is sufficient time for axonal regeneration, typically within a few weeks. In space, there is a histopathological change limited to localized demyelination in nerves lined by epineurium and myelinated by Schwann cells. Nerves distal to the spine qualify as nerves to which the term neurapraxia can apply; however, cranial nerves and spinal nerve roots (including cauda equina) are inconsistent with this owing to the variability in myelinating cells along their course (oligodendroglia proximally, i.e., central glial segment), the absence of an epineurial covering, and exposure to cerebrospinal fluid.
Advances in sports neurological injuries: a call to expand focus beyond traumatic brain injuries to peripheral nerve injuries
Texakalidis, Pavlos , Spinner, Robert J., Davis, Gavin A. , Spinner, Robert J. , Davis, Gavin A

Mayo Clinic

Journal of Neurosurgery | January 24, 2026 | Volume: 144 | Issue: 6 | Pages: 1523-1527

10.3171/2025.9.jns251880 | PMID 41576375 Get It